PlainPill

Tudca

The short answer. Most people who report on Tudca say it helped (80% of 32). It is most often used for digestion: 86% of 7 reports say that improved. It is well studied — 4 meta-analyses on PubMed.

What users report
80%helped32 reports · medium confidence
25 helped5 mixed2 didn't help

From 158 mentions in total — the rest didn't say how it went and aren't counted.

Clinical research
AStrong research base
4
meta-analyses
14
RCTs
1,049
papers

What Tudca does, according to users

Of the people who reported each effect, the share who said it got better.

What the research says

Systematic reviews and meta-analyses from PubMed, with their published conclusions.

AStrong research base

3+ meta-analyses or systematic reviews and 10+ randomized controlled trials in humans. The grade measures how much human research exists — read the conclusions below for what it found. 4 meta-analyses on PubMed ↗ · 14 randomized trials ↗

Curr Neuropharmacol · 2024 · Meta-analysis / systematic review
Neuroprotective Effect of Tauroursodeoxycholic Acid (TUDCA) on In Vitro and In Vivo Models of Retinal Disorders: A Systematic Review

Conclusion: This systematic review demonstrated that TUDCA has neuroprotective effect on in vivo and in vitro models of retinal disorders, reinforcing the currently available evidence that TUDCA could be a promising therapeutic agent in retinal diseases treatment. However, well designed clinical trials are necessary to appraise the efficacy of TUDCA in clinical setting.

PubMed 37691227 ↗
Int J Mol Sci · 2026 · Meta-analysis / systematic review
TUDCA and 4-PBA in Preclinical Models of Beta-Cell Secretory Failure: A Systematic Review and Bayesian Meta-Analysis

Conclusion: Because no source report documents blinding of outcome assessment, the pooled estimate should be read as an upper bound. In conclusion, TUDCA and 4-PBA act as chemical chaperones that alleviate ER stress and may prevent terminal UPR activation and preserve the beta-cell exocytotic machinery, positioning them as candidate disease-modifying agents that merit confirmatory clinical evaluation.

PubMed 42653271 ↗
Brain Behav Immun · 2022 · Meta-analysis / systematic review
From dried bear bile to molecular investigation: A systematic review of the effect of bile acids on cell apoptosis, oxidative stress and inflammation in the brain, across pre-clinical models of neurological, neurodegenerative and neuropsychiatric disorders

Conclusion: In addition, findings suggest that all the three bile acids would be equally beneficial in models of Huntington's disease, whereas UDCA and TUDCA would be more beneficial in models of Parkinson's disease and Alzheimer's disease, while GUDCA in models of bilirubin encephalopathy and TUDCA in models of depression. Overall, this review confirms the therapeutic potential of UDCA, GUDCA and TUDCA in neurological, neurodegenerative and neuropsychiatric disorders, proposing bile acids as potential alternative therapeutic approaches for patients suffering from these disorders.

PubMed 34601012 ↗
BMC Ophthalmol · 2026 · Meta-analysis / systematic review
Retinal changes and treatment in ocular alkali burn: a systematic review of animal models and case reports summary

Conclusion: Retinal injury is a significant but under-recognized consequence of severe OAB. Preclinical studies demonstrate that treatments which offer neuroprotective and anti-inflammatory properties mitigate retinal damage in OAB models. However, clinical evidence remains limited. These findings underscore the importance of early retinal evaluation in OAB and highlight the need for future clinical studies to validate and implement effective treatment strategies.

PubMed 42387427 ↗
Registered clinical trials

44 human trials on ClinicalTrials.gov test Tudca — 21 completed, 5 recruiting now. See all on ClinicalTrials.gov ↗

Reports to the FDA

Adverse-event reports about supplements containing it, submitted to the US FDA by consumers and doctors.

6 reports name a product containing Tudca (2021–2026); 1 involved hospitalization or worse. Most often reported:

  • Fatigue · 2
  • Condition aggravated · 2
  • Malaise · 1
  • Abdominal pain upper · 1
  • Nasal congestion · 1
  • Alanine aminotransferase increased · 1

A report doesn't prove the supplement caused the problem — many products contain several ingredients, and these counts can't tell you how often it happens. Source: FDA CAERS ↗ · raw reports (openFDA) ↗.

What government agencies say

Official records from US, Canadian and EU regulators, each linked to its source.

US government research funding (NIH)

NIH has funded 1 research project with Tudca in the title, $43,647 in total (2011–2011). NIH RePORTER ↗

Dosage people report

As stated by users — not a recommendation. Follow the label or your doctor.

250 mgmorning
500 mgas reported
500 mgnightly
1 gdaily for a month or two
250-500 mgdaily
250 mgas reported

Reported side effects

How often each side effect came up across all reports.

liver stress ×1bad taste ×1h2s overgrowth ×1

What users say

First-hand experiences, quoted verbatim. We show one positive and one negative where both exist.

“While I do take TUDCA primarily for liver health, anecdotally I've noticed... Slight increase in sense of overall wellbeing.”
HelpedRead the discussion ↗
“I took NAC, taurine, tudca and methylated B vitamins. All these fed and aggravated my hydrogen sulfide overgrowth.”
Didn't helpRead the discussion ↗
“I went 1g a day in a single dose for a month or two and then that's it... Personally that regimen has helped me cure my fatty liver.”
HelpedRead the discussion ↗
“my bloodwork says otherwise. ... I run tudca too and it works great for me.”
HelpedRead the discussion ↗
Read more Tudca reviews →
Top discussions (5)

Tudca compared

Other options for digestion

Sources

User data from public discussions; research from PubMed. Information only, not medical advice — talk to a doctor before starting, stopping or combining anything. Data updated October 5, 2026. How we rate